BioMarin Pharmaceutical (BMRN) vs Corcept Therapeutics (CORT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Corcept Therapeutics (CORT) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 32.4% versus a gain of 0.9%. Over five years, CORT leads with a +496.8% price change compared with -27.3% for BMRN. Corcept Therapeutics is the larger company by market cap ($12.93 billion vs $10.69 billion), about 1.2 times the size, while BioMarin Pharmaceutical is growing revenue faster (+12.9% vs +12.8%).
On valuation, BioMarin Pharmaceutical trades at a lower forward P/E (8.3x vs 27.2x for Corcept Therapeutics). Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus 10.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRN | CORT |
|---|---|---|
| Share price | $55.20 | $119.60 |
| Market cap | $10.69B | $12.93B |
| 1-day change | -1.81% | +0.03% |
| YTD return | -7.12% | +243.68% |
| 1-year return | +0.91% | +32.42% |
| 5-year return | -27.26% | +496.81% |
| P/E ratio (TTM) | 149.19 | 265.78 |
| Forward P/E | 8.34 | 27.17 |
| EPS (TTM) | $0.37 | $0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.22B | $761.41M |
| Revenue growth (YoY) | +12.87% | +12.79% |
| Net income (latest FY) | $348.90M | $99.65M |
| Gross margin | 77.73% | 98.30% |
| Operating margin | 12.71% | 5.88% |
| Net margin | 10.83% | 13.09% |
| 52-week high | $70.98 | $126.38 |
| 52-week low | $49.26 | $28.66 |
| Distance from 52-week high | -22.23% | -5.36% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +65.98% | +17.89% |
| Average volume | 2.00M | 1.31M |
| Shares outstanding | 193.57M | 108.10M |
| Employees | 3,221 | 730 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CORT has outperformed BMRN by 31.5 percentage points over the past year.
- Corcept Therapeutics trades at a higher earnings multiple (265.8x vs 149.2x trailing P/E).
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
BMRN vs CORT FAQ
Which is bigger, BioMarin Pharmaceutical or Corcept Therapeutics?
Corcept Therapeutics (CORT) is larger, with a market capitalization of $12.93B compared with $10.69B for BioMarin Pharmaceutical (BMRN).
Which stock has performed better over the past year, BMRN or CORT?
CORT returned +32.42% over the past 12 months, compared with +0.91% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMRN or CORT?
BMRN has the lower trailing P/E at 149.2, versus 265.8 for CORT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BioMarin Pharmaceutical and Corcept Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.